Fingolimod (FTY720) HCl

For research use only. Not for use in humans.

目录号:S5002 中文名称:盐酸芬戈莫德

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Fingolimod (FTY720) HCl是一种S1P拮抗剂,在K562 和 NK细胞中IC50为0.33 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 747.57 现货
RMB 806.22 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Fingolimod (FTY720) HCl发表文献88篇:

产品安全说明书

S1P Receptor抑制剂选择性比较

生物活性

产品描述 Fingolimod (FTY720) HCl是一种S1P拮抗剂,在K562 和 NK细胞中IC50为0.33 nM。
靶点
S1P receptor [1]
(K562, NK cells )
0.033 nM
体外研究

S1P 作用于K562细胞,抑制NK细胞裂解。多种浓度 FTY720可逆转S1P的抑制作用,IC50为173 nM。此外, 10 nM FTY720 单独温育时,对共刺激分子的表达没有任何影响。通过比较S1P的作用效果与S1P和 FTY720联合作用效果,FTY720 可逆转S1P诱导的 HLA-I 表达提高,同时对于细胞百分数和MFI。[1]培养基和高剂量 FTY720-P也增强 TGF-β1水平。在高剂量FTY720-P 组别中可上调TGF-β1 和 Foxp3 mRNA的表达。在培养基和高剂量FTY720-P 组别中的效应 T(Teff)细胞增殖受抑制,Treg/Teff细胞比率为1:1。比率为1:1时,高剂量 FTY720 组别中的Teff细胞也受抑制。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells M2PVNmZ2dmO2aX;uJIF{e2G7 NG\Ue21C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJIh2dWGwIGWyU3Mh[2WubIOgZ48u\XiycnXzd4lv\yCnR1\QJIF{e2W|c3XkJIF{KHKnY3XweI9zKGmwdHXycoFtcXqjdHnvckBqdnSxIHP5eI9xdGG|bTD1d4lv\yCKb3XjbJN1KGS7ZTDzeIFqdmmwZzygSWM2OD1yLkCwNkDPxE1w NH3oTlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGwOFE1PCd-MkKxNFQyPDR:L3G+
human PC3 cells MVLDfZRwfG:6aXRCpIF{e2G7 NU[3TFRRPzJiaB?= M4LJeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;OT64JO69VS5? NFPHdXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human NALM6 cells NVXRNGltS3m2b4TvfIlkyqCjc4PhfS=> NETQfow4OiCq NFTnNYFEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3u[YdifGm4ZTDoeY1idiCQQVzNOkBk\WyuczDh[pRmeiB5MjDodpMh[nlidnn0ZYwh\HmnIHX4Z4x2e2mxbj;mcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:QS54IN88UU4> NVy2[WJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human CCRF-CEM cells NWmyNHVsS3m2b4TvfIlkyqCjc4PhfS=> MkPTO|IhcA>? Mo\ZR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hS0OURj3DSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwODFOwG0v M3zYSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human SUP-B15 cells MlOyR5l1d3SxeHnjxsBie3OjeR?= MmntO|IhcA>? Mn\XR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvcH;zbZRqfmViaIXtZY4hW1WSLVKxOUBk\WyuczDh[pRmeiB5MjDodpMh[nlidnn0ZYwh\HmnIHX4Z4x2e2mxbj;mcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Pi56IN88UU4> NYjPOVJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human DU145 cells NFjCcHFEgXSxdH;4bYPDqGG|c3H5 M3PqSFczKGh? NWftcXo3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvPSEQvF2u M1\XVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human BV173 cells MYPDfZRwfG:6aXRCpIF{e2G7 NVy2OldKPzJiaB?= MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2yb4PpeIl3\SCqdX3hckBDXjF5MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhfmm2YXyg[JlmKGW6Y3z1d4lwdi:obH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9Ok4{KM7:TT6= M{TJUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human BLIN-1 cells MXHDfZRwfG:6aXRCpIF{e2G7 MlvOO|IhcA>? MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2wZXfheIl3\SCqdX3hckBDVEmQLUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVUvPSEQvF2u MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N|I9N2F-
mouse bone marrow cells MXHDfZRwfG:6aXRCpIF{e2G7 NU\lSotXPzJiaB?= M4\xOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUj3BRmwh\nW|aX;uJJBzd3SnaX6gNVkxKGW6cILld5NqdmdibX;1d4Uh[m:wZTDtZZJzd3diY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuN{DPxE1w NF3mRmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
Sf9 insect cells M1XwWmZ2dmO2aX;uJIF{e2G7 Mn7nNUBp NH3icI5KdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGOxVGwhMDZ{IITvJFU3QCliZYjwdoV{e2WmIHnuJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdiU{HQJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{ NVjjWXJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFk5OTRpPkK0PFA6QDF2PD;hQi=>
mouse MN9D cells NFixRWhHfW6ldHnvckBie3OjeR?= NIfzZZA2KM7:TR?= MVjJcoR2[3Srb36gc4YhWFB{QTDjZZRidHm2aXOgd5VjfW6rdDDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXN NFnpWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
rat PC12 cells MWrGeY5kfGmxbjDhd5NigQ>? NVTQ[442PSEQvF2= NIi2VoI{OCC2bzCxNlAhdWmwcx?= NU[5NmpPUW6mdXP0bY9vKG:oIGDQNmEh[2G2YXz5eIlkKHO3YoXubZQh[WO2aY\peJkhcW5icnH0JHBEOTJiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bp[XSnIHzleoVtKGG2IEWgeW0hdWWjc4Xy[YQhOzBidH:gNVIxKG2rboOu NXjs[VdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
mouse MN9D cells MWTGeY5kfGmxbjDhd5NigQ>? M1rOfFAvOTZizszN M{nYVFI1KGh? MXPO[ZVzd3C{b4TlZ5RqfmViYXP0bZZqfHliaX6gcY92e2ViTV65SEBk\WyuczDhd5Nme3OnZDDhd{B{fGmvdXzheIlwdiCxZjDCSG5HKGW6cILld5Nqd25iYYSgNE4yPiC3TTDh[pRmeiB{NDDodpM> NUHWN214RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
mouse MN9D cells M33PbGZ2dmO2aX;uJIF{e2G7 MXSwMlE3KM7:TR?= MkjJO|IhcA>? Ml\KUoV2em:ycn;0[YN1cX[nIHHjeIl3cXS7IHnuJI1wfXOnIF3OPWQh[2WubIOgZZN{\XO|ZXSgZZMh[myxY3vpcochd2ZiVF7GMYFteGijIHHzd49kcWG2ZXSgeI95cWOrdImgZZQhOC5zNjD1UUBi\nSncjC3NkBpenNiYomgWJJ6eGGwIHLseYUhe3SjaX7pcocv NEn4OZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
CHO MV;GeY5kfGmxbjDhd5NigQ>? MVvEbZNxdGGlZX3lcpQhd2ZiW{OzVH1{eGirbnfvd4lv\SBzIIDoc5NxcGG2ZTDmdo9uKGi3bXHuJHMyWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{whUUN3ME2wMlg1|ryPLh?= NFLOR3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOyd-MUW2NVU2OTN:L3G+
CHO M1PPV2Z2dmO2aX;uJIF{e2G7 NWPt[|BHTGm|cHzhZ4Vu\W62IH;mJHs{O1Cfc4DobY5od3OrbnWgNUBxcG:|cHjheIUh\nKxbTDoeY1idiCVMWC1JJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNuIFnDOVA:Oi5zzszNMi=> Mnj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVMoRjF3NkG1OVE{RC:jPh?=
Jurkat MlqxSpVv[3Srb36gZZN{[Xl? M4SyRlE5KGi{cx?= M{ftXHJmfmW{c3HsJI9nKGmwaHnibZRqd25ib3[gcYl1d2Oqb37kdolidCCodX7jeIlwdiCrbjDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiMUigbJJ{KGmwIIDy[ZNmdmOnIH;mJHouXkGGLX\tby=> M{TWZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NECwOVU2Lz5zN{SwNFU2PTxxYU6=
T-cells MnXTSpVv[3Srb36gZZN{[Xl? MX[5OkBpenN? MXvJcY12dm:|dYDwdoV{e2m4ZTDhZ5Rqfmm2eTDpckBDSUyEL3OvR|U4SkxxNjDtc5V{\SCWIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wyub3HueIlo\W5vaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhQTZiaILzJIJ6KG2nYYP1dolv\yCdM1jdeIh6dWmmaX7lJJVxfGGtZTDifUBucXinZDDsfY1xcG:leYTlJJJm[WO2aX;uJIF{e2G7LDDJR|UxRTBwMEC2Ne69VS5? M1W1R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
SK-BR-3 MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Ml\mO|ghcHK| NFTkbIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMWJTNTNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzhiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR|UxRTYQvF2u Mn\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
MDA-MB-231 MoLtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Ml;DO|ghcHK| M4X0e2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5ODDodpMh[nliV2PUMVEh[XO|YYmsJGlEPTB;Nd88UU4> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
HCT116 NFv2UFlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXG3PEBpenN? MnjKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|ghcHK|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w NXHE[o9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
SW620 NGjNfJJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnvIO|ghcHK| NHnG[2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOlIxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF02|ryPLh?= NIfF[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
MCF7 NH\nRVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVXIVJdbPzhiaILz Mm[1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEe4JIhzeyCkeTDXV3QuOSCjc4PhfUwhUUN3ME21{txONg>? M3uwfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
LNCAP-AI NIC2O5RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXq3PEBpenN? NHLxbZZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBpfW2jbjDMUmNCWC2DSTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5ODDodpMh[nliV2PUMVEh[XO|YYmsJGlEPTB;Nd88UU4> NWnGfm5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
MGC803 MnTGRY51cXS3bX;yJIF{e2G7 MYexNEBu\y:tZx?= MUWyNEBl[Xm| MlrWRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfDPFA{KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eY1weiCpcn;3eIgh[XRiMUCgcYcwc2diZn;yJFIxKGSjeYO= M{fk[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
U2OS MVLGeY5kfGmxbjDhd5NigQ>? Mnr0NVghcHK| MYTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGOxVFEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFXES|Eu[myjIGWyU3Mh[2WubIOgbY5kfWKjdHXkJIZweiBzODDodpMheHKrb4KgeI8hT2WwQnzhfoVzKHO3YoP0doF1\SCjZHTpeIlwdiCkeTDi[ZRiNWG{cnXzeIlvKHKnY4L1bZRu\W62IHHzd4F6NCCHQ{WwQVAvODB5Mt88UU4> M2LBbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Nki3OFg4Lz5{Nk[4O|Q5PzxxYU6=
FL5.12A MUTDfZRwfG:6aXPpeJkh[XO|YYm= NFfQTJI1QCCqcoO= MkD2R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSmw2NjF{QTDj[YxteyCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9Nk41|ryPLh?= M3PnblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEe1OVM1Lz5{N{S3OVU{PDxxYU6=
SH-SY5Y NEfGXItEgXSxdH;4bYNqfHliYYPzZZk> M{\hZlI1KGi{cx?= M1vXSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTUQvF2u NHf2emk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
SK-N-SH NU\nNHR3S3m2b4TvfIlkcXS7IHHzd4F6 Mkf0NlQhcHK| MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNVOKIHPlcIx{KG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBkenm|dHHsMZZqd2yndDDzeIFqdmmwZzDiZZNm\CCjc4PhfUwhTUNzME2wMlU2|ryPLh?= NIrHSGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
U118MG NUTvNZlVS3m2b4TvfIlkcXS7IHHzd4F6 NWHtTZRROjRiaILz M4PIO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHUyOTiPRzDj[YxteyCvZXHzeZJm\CCjZoTldkAzPCCqcoOgZpkh[3K7c4ThcE13cW:uZYSgd5RicW6rbnegZoF{\WRiYYPzZZktKEWFMUC9NE43Oc7:TT6= Ml\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SH-SY5Y MYjGeY5kfGmxbjDhd5NigQ>? NFXTRVhC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[0GPUDDs[ZZmdCCjdDDFR|ExKGK7IHTpdoVkfCCrbX31co9ie3OjeR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
U118MG NXnreplMTnWwY4Tpc44h[XO|YYm= M{i1SmFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gWVEyQE2JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJINCVVBibHX2[Ywh[XRiRVOxNEBjgSCmaYLlZ5QhcW2vdX7vZZN{[Xl? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
SK-N-SH NXXMWFJwTnWwY4Tpc44h[XO|YYm= NH7rW3JC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJIh2dWGwIGPLMW4uW0hiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ2FOWCCuZY\lcEBifCCHQ{GwJIJ6KGSrcnXjeEBqdW23bn;hd5NigQ>? M3T4WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
HEK293 MlTwSpVv[3Srb36gZZN{[Xl? MWqxPEBpenN? NGDBTlZC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClQV3QJIxmfmWuIHH0JGVEOTBiYX\0[ZIhOThiaILzJIJ6KEOURT3y[ZNxd26|aY\lJJJmdmmubHGgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NV7VdGttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
SJ-GBM2 NInTUJVyUFSVIHHzd4F6 NUnqVFNleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> M3fPVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NEjaS5JyUFSVIHHzd4F6 NGHEfVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MljYdWhVWyCjc4PhfS=> MojhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MlzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NVPZdFVHeUiWUzDhd5NigQ>? M4e4WZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= MmOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MVTxTHRUKGG|c3H5 M4XQcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NE\Iemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NGTrOm9yUFSVIHHzd4F6 NH\FcYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NGPjV5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NVmwPHJ2eUiWUzDhd5NigQ>? NVzhWldQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NIWwSIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MoLvdWhVWyCjc4PhfS=> MnTYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= MmHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 M1L1fJFJXFNiYYPzZZk> Mlz2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| NULxN5NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NVSwUY1FeUiWUzDhd5NigQ>? M4jXOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NWnuSVZzeUiWUzDhd5NigQ>? NF\L[3JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NF;QXFhyUFSVIHHzd4F6 M3z4N5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NY[wTIRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD M4fiOpFJXFNiYYPzZZk> M1Wyc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? M1LR[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NV3iXZdIeUiWUzDhd5NigQ>? Moi3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 M2LRSpFJXFNiYYPzZZk> MmjsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NGTodoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NHnabZVyUFSVIHHzd4F6 NUjkXI5reUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NEnrToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
FL5.12 NF2w[GREgXSxdH;4bYNqfHliYYPzZZk> MYm0PEBpenN? NIe0Xo1EgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KESDUFmgc5IheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi5zzszNMi=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ7Mki5PEc,OzB{OUK4PVg9N2F-
FL5.12 Mn;jR5l1d3SxeHnjbZR6KGG|c3H5 M2fsT|ExKHWP NYr2dYozOyCqcoO= MmPlR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSmw2NjF{IHPlcIx{KGG|c3Xzd4VlKGG|II\hZ5VwdGViZn;ycYF1cW:wIHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4DpZ{BidmGueYPpdy=> NYG0TXQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVI5QThpPkOwNlkzQDl6PD;hQi=>
FL5.12 Ml:wR5l1d3SxeHnjbZR6KGG|c3H5 MYGyMlUhfU1? NY\E[444OyCqcoO= M2rXTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMjDj[YxteyCjc4Pld5Nm\CCjczD2ZYN2d2ynIH\vdo1ifGmxbjDheEAzNjVidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ M3T3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkmyPFk5Lz5|MEK5Nlg6QDxxYU6=
HepG2 MVfxTHRUKGG|c3H5 MUPI[ZBIOiClZXzsd{B3cWGkaXzpeJkheUiWUzDmc5IhYmmtYTD2bZJ2eyCrbnjpZol1d3K| MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OzJ{OUW0OUc,OzN{Mkm1OFU9N2F-
CHO NHfzPYpHfW6ldHnvckBie3OjeR?= MX;B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGOxVFMhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPIU{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClYXzjbZVuKG[udYigZpkh[WWzdX;ybY4u\GW{aY\l[EBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUC9Nk42OTF6Od88UU4> NIDmbFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OTR6NUSvK|5EcEWPQly8M4E,
CHO NFPiO2FHfW6ldHnvckBie3OjeR?= NIH2O3RC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDVicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZYxkcXWvIH\seZgh[nliYXXxeY9zcW5vZHXybZZm\CCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:Oy5zNkKyPO69VS5? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNVQ5PTRxJ{7DbGVOSkx:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 ; 

PubMed: 25344679     


FTY720 induces expression of p16 and p27 and reduces expression of cyclin D1, CDK4, cyclin E and CDK2. CC cells were treated with FTY720 at the indicated concentrations for 24 h. Lysates were then prepared immediately and analyzed by western blotting for cyclin D1, CDK4, cyclin E, CDK2, p16 and p27. β-Actin was used as the internal control. All assays were done in triplicate. 

p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; 

PubMed: 25344679     


CC cells were treated for 24 h with or without FTY720 and analyzed for the indicated protein by western blotting. 

p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin; 

PubMed: 28717222     


Dose-dependent effects of FTY720 on the phosphorylation of Akt, mTOR, GSK3β, and IKKα/β, and the expression of NF-κB, and survivin in SCC2095 cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium for 24h, and cell lysates were immunoblotted as described in Material and Methods

25344679 28717222
Immunofluorescence
N-cadherin / Vimentin ; 

PubMed: 25344679     


Single and merged images show immunofluorescence staining of N-cadherin (green) and vimentin (red). The cell nucleus is stained blue by DAPI.

NF-κB; 

PubMed: 28717222     


Effect of FTY720 on the nuclear translocation of NF-κB. SCC2095 cells were treated with 5μM FTY720 for 24h, stained with anti-NF-κB, and examined by confocal microscopy.

25344679 28717222
Growth inhibition assay
Cell viability; 

PubMed: 28717222     


Effect of FTY720 at the indicated concentrations on the viability of oral cancer cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium in 96- well plates at 24h, and cell viability was assessed by MTT assays. Points, means; bars, S.D. (n=6). *P<0.01 compared to the control group.

28717222
体内研究 FTY720 治疗使用早期疾病模型Ph+而不是 Ph- ALL移植瘤,效果是肯定的。 FTY720 作用于使用早期疾病模型的Ph+ ALL移植瘤,显著降低疾病负担。在所有早期疾病中,FTY720处理的Ph+人类ALL移植瘤降低80±12%。相反, FTY720处理小鼠,与对照组相比,使用四组分开独立的人类 Ph- ALL 移植瘤,减少白血病发生率。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: 未成熟的 DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 小时
  • Method: 未成熟的 DCs原封不动,或与 2 μM S1P, 10 nM FTY720, 10 nM SEW2871或S1P 与这些药剂的联和温育4小时。使用1 μg/mL LPS作为对照。冲洗细胞,在96孔板(v-型底,每孔 2 × 105 个细胞)中温育,再次冲洗,再悬浮在含0.1%叠氮化钠的 PBS buffer 中。使用1 μg/mL FITC标记的小鼠抗人CD80, CD83, CD86, HLA-class I, HLA-DR, 1 μg/mL HLA-E标记, 使用1 μg/mL FITC标记的小鼠 IgG 作为对照。细胞冲洗两次,在流式细胞仪中检测。根据同型对照 FITC标记的小鼠IgG进行标记。使用多种NK 细胞激活受体的抗体对NK细胞进行染色,或使细胞原封不动或与 2 μM S1P 温育4小时,冲洗,使用1 μg/mL PE标记的小鼠抗人NKp30 (CD337), NKp44 (CD336), NKG2D (CD314),在4 oC下染色45分钟,使用1 μg/mL PE标记的小鼠IgG1作为对照。也使用1 μg/mL FITC标记的抗-杀伤抑制性受体(KIR)/CD158 抗体(识别KIR2DL2, KIR2DL3, KIR2DS2 和KIR2DS4)对NK细胞进行染色,使用FITC标记的小鼠 IgG作为对照。冲洗细胞两次,在流式细胞仪中检测。
    (Only for Reference)
动物实验: [3]
- 合并
  • Animal Models: 携带ALL细胞的NOD/SCIDγc−/−小鼠
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (200.63 mM)
Water 69 mg/mL (200.63 mM)
Ethanol ''69 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 343.9
化学式

C19H33NO2.HCl

CAS号 162359-56-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03345940 Terminated Drug: Fingolimod|Drug: Dimethyl Fumarate Relapsing Remitting Multiple Sclerosis Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova April 30 2017 Phase 4
NCT02575365 Terminated Drug: 05 mg Fingolimod Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 16 2016 Phase 4
NCT02490930 Completed Drug: Fingolimod Glioblastoma|Anaplastic Astrocytoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2015 Early Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

S1P Receptor Signaling Pathway Map

相关S1P Receptor产品

Tags: 购买Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl供应商 | 采购Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl价格 | Fingolimod (FTY720) HCl生产 | 订购Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID